Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent XXXX .

@entity1 @entity137 @entity5 @entity294 @entity86 @entity418 @entity1199 @entity221
@entity418 is one of the most common @entity5 . However, @entity86 are still resistant to currently available radiochemotherapy. We recently reported a study on the initial clinical efficacy of locoregional adoptive immunotherapy for advanced @entity418 . We report here our clinical experience of remarked responses in distant metastatic lesions in a @entity1 with @entity5 after receiving this immunotherapy. A male @entity1 underwent curative surgery, and presented with multiple recurrent metastases in the supraclavicular lymph nodes (LNs), liver, and abdominal aortic LNs. Autologous @entity5 -activated lymphocytes (AuTLs) generated ex vivo were regionally injected into supraclavicular LNs every 2 weeks 13 times. Mean numbers of the administrated cells were 0.8 x 10(9) cells/injection. AuTLs established from peripheral blood lymphocytes stimulated by autologous @entity5 cells with @entity1199 were tested for their @entity137 before every treatment. During immunotherapy, Grade 2 @entity294 and @entity221 were observed. The clinical partial responses were obtained in all lesions and were sustained for 11 months. Because clinical @entity137 was tolerable, this immunotherapy might be useful for @entity1 with far-advanced @entity418 .
